Verge Genomics Overview
- Founded
-
2015
- Status
-
Private
- Employees
-
56
- Latest Deal Type
-
Series B1
- Latest Deal Amount
-
$98M
- Investors
-
31
Verge Genomics General Information
Description
Developer of a drug discovery platform designed to accelerate the development of life-saving treatments for neurodegenerative diseases. The company's platform utilizes machine learning to develop therapeutics, specifically for neurological diseases and can analyze datasets of any size, to identify new targets and predict effective drugs, enabling healthcare providers to improve patient outcomes as well as fundamentally bend the cost curve of pharmaceutical development.
Contact Information
Website
www.vergegenomics.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Other Healthcare Technology Systems
Biotechnology
Primary Office
- Two Tower Place
- Suite 950
- San Francisco, CA 94080
- United States
Verge Genomics Timeline
Verge Genomics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series B1) | 15-Dec-2021 | $98M | 00000 | 00000 | Completed | Pre-Clinical Trials |
| 6. Later Stage VC (Series B) | 01-Nov-2021 | 000.00 | Completed | Pre-Clinical Trials | ||
| 5. Later Stage VC (Series A) | 30-Jun-2020 | 000.00 | Completed | Pre-Clinical Trials | ||
| 4. Early Stage VC (Series A1) | 25-Jan-2019 | 000.00 | 000.00 | Completed | Pre-Clinical Trials | |
| 3. Early Stage VC (Series A) | 16-Jul-2018 | 0000 | 000.00 | 0000 | Completed | Pre-Clinical Trials |
| 2. Seed Round | 28-Oct-2015 | $4M | $4.12M | Completed | Startup | |
| 1. Accelerator/Incubator | 18-Aug-2015 | $120K | $120K | 00.000 | Completed | Startup |
Verge Genomics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B1 | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A6 | 000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 0.00 |
| Series A5 | 000,000 | 00.000000 | 00 | 00.0 | 00.0 | 00 | 00.0 | 0.000 |
| Series A4 | 00,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 0.000 |
| Series A3 | 0,000,000 | 00.000000 | 00 | 00.0 | 00.0 | 00 | 00.0 | 0.000 |
| Series A2 | 1,698,104 | $0.000100 | 6% | $2.65 | $2.65 | 1x | $2.65 | 3.69% |
| Series A1 | 13,622,216 | $0.000100 | 6% | $3.31 | $3.31 | 1x | $3.31 | 29.62% |
Verge Genomics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a drug discovery platform designed to accelerate the development of life-saving treatments for neurodegener
Drug Discovery
San Francisco, CA
56
As of 2022
00000
0000
0000-00-00
00000000000
00000
00000
irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Except
0000 000000000
Salt Lake City, UT
00
As of 0000
00000
000000000
00000
00 000
por incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation
0000 000000000
Guilford, CT
00
As of 0000
0000
000000000 -
0000
Add Comparison
Verge Genomics Competitors (50)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Clene Nanomedicine | Formerly VC-backed | Salt Lake City, UT | 00 | 00000 | 000000000 | 00000 |
| 00 000000000000 | Venture Capital-Backed | Guilford, CT | 00 | 0000 | 000000000 - | 0000 |
| 0000000 | Venture Capital-Backed | Singapore, Singapore | 00 | 00000 | 00000000000 | 00000 |
| 000000 | Venture Capital-Backed | Seattle, WA | 00 | 000.00 | 00000000000 | 000.00 |
| 0000000 | Venture Capital-Backed | Framingham, MA | 00 | 000.00 | 00000000000 | 000.00 |
Verge Genomics Patents
Verge Genomics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021207804-A1 | Substituted pyrazolo-pyrimidines and uses thereof | Pending | 13-Jan-2020 | 0000000000 | |
| CA-3167339-A1 | Substituted pyrazolo-pyrimidines and uses thereof | Pending | 13-Jan-2020 | 0000000000 | |
| EP-4090426-A1 | Substituted pyrazolo-pyrimidines and uses thereof | Pending | 13-Jan-2020 | 0000000000 | |
| EP-4069699-A1 | Fused tricyclic heterocyclic compounds as inhibitors of pikfyve kinase useful for the treatment of neurological diseases | Pending | 05-Dec-2019 | 00000000000 | |
| US-20170360805-A1 | Motor-associated neurodegenerative disease and methods of treatment | Inactive | 16-Jun-2016 | A61K31/573 |
Verge Genomics Executive Team (10)
Verge Genomics Board Members (9)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alfred Sandrock Jr. | Self | Board Member | 000 0000 |
| Alice Zhang Ph.D | Verge Genomics | Co-Founder, Chief Executive Officer & Board Member | 000 0000 |
| Andrew Allen Ph.D | Self | Board Member | 000 0000 |
| Dave Madge | WuXi AppTec | Board Observer | 000 0000 |
| Emily Melton | Self | Board Member | 000 0000 |
Verge Genomics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Verge Genomics Investors (31)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| BlackRock | Asset Manager | Minority | 000 0000 | 000000 0 | |
| Cercano Management | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Eli Lilly | Corporation | Minority | 000 0000 | 000000 0 | |
| Merck Global Health Innovation Fund | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
| Section 32 | Venture Capital | Minority | 000 0000 | 000000 0 |